Angiotensin II: A Multimodal Approach to Vasoplegia in a Cardiac Setting

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Vasoplegia, a form of distributive shock, presents limited therapeutic options for patients with cardiac dysfunction, particularly those post-heart transplant or ventricular assist device (VAD) implantation.
• Conventional vasopressors may be insufficient or inappropriate for managing vasoplegia in these complex cardiac patients.

Observation:

• Two critical cardiac patients experiencing vasoplegia were treated with angiotensin II.
• These patients had undergone orthotopic heart transplant or VAD implantation and had cardiac dysfunction.

Findings:

• Angiotensin II effectively corrected vasoplegia in both presented cases.
• The use of angiotensin II proved vital in managing refractory vasoplegia in these specific patient populations.

Implications:

• Angiotensin II may represent a crucial therapeutic strategy for vasoplegia in post-cardiac surgery or VAD patients.
• Further research into angiotensin II's role in managing distributive shock in advanced cardiac disease is warranted.